Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Aurobindo Pharma to spin-off injectable business

The company registers profit of Rs 18.6 crore in Q1

BS B2B Bureau  |  Mumbai 

  • ALSO READ

    Aurobindo Pharma surges on strong Q1 results

    Aurobindo posts Rs 18.6 cr net profit

    Aurobindo Pharma bets big on injectables from Unit-IV plant

    Aurobindo, Natco Pharma get FDA nod for migraine drug

    Aurobindo net flat at Rs 108 cr

The board has considered the option of spin-off of the to a wholly owned subsidiary as a going concern, in order to strengthen and provide focused growth to the injectable business and to leverage strategic opportunities.
 
Meanwhile, reported a consolidated net profit of Rs 18.6 crore for the quarter ended June 30, 2013 (Q1) against a net loss of Rs 129 crore in the corresponding quarter last fiscal.
 

Aurobindo Pharma to spin-off injectable business

The company registers profit of Rs 18.6 crore in Q1

The company registers profit of Rs 18.6 crore in Q1
The board has considered the option of spin-off of the to a wholly owned subsidiary as a going concern, in order to strengthen and provide focused growth to the injectable business and to leverage strategic opportunities.
 
Meanwhile, reported a consolidated net profit of Rs 18.6 crore for the quarter ended June 30, 2013 (Q1) against a net loss of Rs 129 crore in the corresponding quarter last fiscal.
 
image